VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced it received comments from the U.S. Food and Drug Administration (FDA) on the confirmatory Registration Study’s ...
Growing body of data on PD-L1 as a cancer biomarker spurs interest Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study VIENNA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results